AULT MILTON C III sold $3K of ALZN

AULT MILTON C III sold 2,000 shares of Alzamend Neuro, Inc. (ALZN) at $1.56 on 2026-08-26.

Original reporting
SEC EDGAR · AULT MILTON C III
Published Aug 31, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALZN
Neutral
high confidence
Mentioned
$ALZN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALZNNeutralLow
01

Why it matters

The director's complete exit may be noted by investors but is unlikely to move the stock materially.

02

Market read

Minor insider sell; low trading relevance.

03

What to watch

Potential upcoming dilution or strategic shift not disclosed.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-31

Background

Form 4 filing discloses insider transactions to the market.

Company-level read

Ticker impact

$ALZNNeutralHigh confidence
Context

Director Ault Milton C III sold 2,000 shares of Alzamend Neuro for $3,116, reducing his holding to zero.

Expected impact

No significant move; possible slight downward pressure.

Evidence & confidence

The sale is small relative to market cap and represents a complete exit, but the amount is trivial and unlikely to affect valuation.

Market effects

None; isolated insider transaction.

None; company is US-listed biotech.

Low; no broader market effect.

Counterpoint

Even small insider sells can signal concerns; monitor upcoming news.

Key entities

  • Alzamend Neuro, Inc.

    US-listed biotech company (ticker ALZN).

  • Ault Milton C III

    Director of Alzamend Neuro.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALZNMed

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMed

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

$ALZNLow

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.